J Portnoy, K Bagstad, H Kanarek, F Pacheco, B Hall, C Barnes
{"title":"药物前治疗可减少吸入性快速免疫治疗中致敏提取物混合物的全身反应发生率。","authors":"J Portnoy, K Bagstad, H Kanarek, F Pacheco, B Hall, C Barnes","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rush immunotherapy, while having many potential benefits, is associated with an increased incidence of systemic reactions.</p><p><strong>Objective: </strong>To determine whether pretreatment with medications reduces the rate of systemic reactions during rush immunotherapy and to identify predictors of such reactions if possible.</p><p><strong>Methods: </strong>We conducted a double-blind, placebo-controlled study of 22 allergic children ages 6 to 18 years who received rush immunotherapy. Active treatment consisted of a combination of H1 and H2 histamine antagonists and a corticosteroid in gelatin capsules given prior to administration of rush immunotherapy whereas placebo patients received lactose. Rush immunotherapy consisted of eight injections of increasing doses of a mixture of allergens to which each patient was skin-reactive over 1 1/2 days. Serial skin tests and peak expiratory flow rate measurements were performed during the procedure. Following the initial series of injections, patients were followed for 8 weeks and had blood drawn at 2-week intervals for measurements of specific IgG and IgE.</p><p><strong>Results: </strong>Systemic reactions were observed in 3 (27%) active and 8 (73%) placebo patients (Fisher's exact test: P = .047). The mean time for systemic reactions was 63 minutes after a previous injection. The most common dose causing a systemic reaction was 0.3 mL of 1:1000 (wt/vol). The best predictors of development of a systemic reaction were degrees of skin sensitivity to the extract before and after premedication. Local reactions were not associated with subsequent systemic reactions. Specific IgG rose by 2 weeks while specific IgE did not change significantly during the 8-week follow-up period. Pretreatment did not change the number of systemic reactions seen with subsequent injections.</p><p><strong>Conclusions: </strong>Premedication significantly reduces the incidence of systemic reactions during rush immunotherapy and is therefore recommended. Degree of skin sensitivity to the injected extract may eventually prove to be a clinically useful predictor for the development of systemic reactions.</p>","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 5","pages":"409-18"},"PeriodicalIF":0.0000,"publicationDate":"1994-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts.\",\"authors\":\"J Portnoy, K Bagstad, H Kanarek, F Pacheco, B Hall, C Barnes\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Rush immunotherapy, while having many potential benefits, is associated with an increased incidence of systemic reactions.</p><p><strong>Objective: </strong>To determine whether pretreatment with medications reduces the rate of systemic reactions during rush immunotherapy and to identify predictors of such reactions if possible.</p><p><strong>Methods: </strong>We conducted a double-blind, placebo-controlled study of 22 allergic children ages 6 to 18 years who received rush immunotherapy. Active treatment consisted of a combination of H1 and H2 histamine antagonists and a corticosteroid in gelatin capsules given prior to administration of rush immunotherapy whereas placebo patients received lactose. Rush immunotherapy consisted of eight injections of increasing doses of a mixture of allergens to which each patient was skin-reactive over 1 1/2 days. Serial skin tests and peak expiratory flow rate measurements were performed during the procedure. Following the initial series of injections, patients were followed for 8 weeks and had blood drawn at 2-week intervals for measurements of specific IgG and IgE.</p><p><strong>Results: </strong>Systemic reactions were observed in 3 (27%) active and 8 (73%) placebo patients (Fisher's exact test: P = .047). The mean time for systemic reactions was 63 minutes after a previous injection. The most common dose causing a systemic reaction was 0.3 mL of 1:1000 (wt/vol). The best predictors of development of a systemic reaction were degrees of skin sensitivity to the extract before and after premedication. Local reactions were not associated with subsequent systemic reactions. Specific IgG rose by 2 weeks while specific IgE did not change significantly during the 8-week follow-up period. Pretreatment did not change the number of systemic reactions seen with subsequent injections.</p><p><strong>Conclusions: </strong>Premedication significantly reduces the incidence of systemic reactions during rush immunotherapy and is therefore recommended. Degree of skin sensitivity to the injected extract may eventually prove to be a clinically useful predictor for the development of systemic reactions.</p>\",\"PeriodicalId\":7931,\"journal\":{\"name\":\"Annals of allergy\",\"volume\":\"73 5\",\"pages\":\"409-18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1994-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of allergy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:快速免疫疗法虽然有许多潜在的益处,但与全身反应发生率增加有关。目的:确定药物预处理是否能降低紧急免疫治疗期间全身反应的发生率,并在可能的情况下确定这些反应的预测因素。方法:我们进行了一项双盲,安慰剂对照研究,22名6至18岁的过敏儿童接受了快速免疫治疗。积极治疗包括H1和H2组胺拮抗剂和明胶胶囊中的皮质类固醇的组合,在给予匆忙免疫治疗之前给予,而安慰剂患者接受乳糖治疗。Rush免疫疗法包括8次注射增加剂量的过敏原混合物,每位患者在1天半内对其皮肤产生反应。在此过程中进行了一系列皮肤试验和呼气流速峰值测量。在最初的一系列注射后,对患者进行了8周的随访,并每隔2周抽血测量特异性IgG和IgE。结果:在3例(27%)活跃患者和8例(73%)安慰剂患者中观察到全身反应(Fisher精确检验:P = 0.047)。前一次注射后出现全身反应的平均时间为63分钟。引起全身反应的最常见剂量是0.3 mL 1:1000 (wt/vol)。全身性反应发生的最佳预测指标是用药前和用药后皮肤对提取物的敏感程度。局部反应与随后的全身反应无关。特异性IgG升高2周,特异性IgE在8周随访期间无明显变化。预处理没有改变随后注射的全身反应的数量。结论:在匆忙免疫治疗期间,预用药可显著降低全身反应的发生率,因此推荐使用。皮肤对注射提取物的敏感程度可能最终被证明是一个临床有用的预测系统反应的发展。
Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts.
Background: Rush immunotherapy, while having many potential benefits, is associated with an increased incidence of systemic reactions.
Objective: To determine whether pretreatment with medications reduces the rate of systemic reactions during rush immunotherapy and to identify predictors of such reactions if possible.
Methods: We conducted a double-blind, placebo-controlled study of 22 allergic children ages 6 to 18 years who received rush immunotherapy. Active treatment consisted of a combination of H1 and H2 histamine antagonists and a corticosteroid in gelatin capsules given prior to administration of rush immunotherapy whereas placebo patients received lactose. Rush immunotherapy consisted of eight injections of increasing doses of a mixture of allergens to which each patient was skin-reactive over 1 1/2 days. Serial skin tests and peak expiratory flow rate measurements were performed during the procedure. Following the initial series of injections, patients were followed for 8 weeks and had blood drawn at 2-week intervals for measurements of specific IgG and IgE.
Results: Systemic reactions were observed in 3 (27%) active and 8 (73%) placebo patients (Fisher's exact test: P = .047). The mean time for systemic reactions was 63 minutes after a previous injection. The most common dose causing a systemic reaction was 0.3 mL of 1:1000 (wt/vol). The best predictors of development of a systemic reaction were degrees of skin sensitivity to the extract before and after premedication. Local reactions were not associated with subsequent systemic reactions. Specific IgG rose by 2 weeks while specific IgE did not change significantly during the 8-week follow-up period. Pretreatment did not change the number of systemic reactions seen with subsequent injections.
Conclusions: Premedication significantly reduces the incidence of systemic reactions during rush immunotherapy and is therefore recommended. Degree of skin sensitivity to the injected extract may eventually prove to be a clinically useful predictor for the development of systemic reactions.